NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Okay, now I’m kinda regretting that I even pointed that out, but that “wordsmith” section from the 10-K bothered me when I originally read it, and then you inadvertently brought it up in this post that I replied to. (which was an excellent rebuttal to ex by the way)

As for disclosing the analysis plan in their top line PR... are you joking? Remember, they've indicated it was phone book sized... how on earth could they disclose the SAP in their PR? They've already disclosed the endpoints in the last Q
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164974255

In my reply, I posted and bolded that exact same section. (page 16 of the 10-K) And yes, it references the endpoint changes, but it does not actually disclose what the new endpoints are, which is my bone of contention.

Did Northwest Bio actually disclose the endpoints? Where does it say what the new endpoints are?

This was under the risk factors in the 10-K:

Quote:

We may not receive regulatory approvals for our product candidates or there may be a delay in obtaining such approvals.

Our products and our ongoing development activities are subject to regulation by regulatory authorities in the countries in which we and our collaborators and distributors wish to test, manufacture or market our products. For instance, the FDA will regulate our product in the U.S. and equivalent authorities, such as the MHRA and EMA will regulate in Europe and other jurisdictions. Regulatory approval by these authorities will be subject to the evaluation of data relating to the quality, efficacy and safety of the product for its proposed use, and there can be no assurance that the regulatory authorities will find our data sufficient to support product approval of DCVax-L or DCVax-Direct. In addition, the endpoint against which the data is measured must be acceptable to the regulatory authorities, and the statistical analysis plan for how the data will be evaluated must also be acceptable to the regulatory authorities. The statistical analysis plan that we submitted to regulators for the Phase III trial embodies a different primary endpoint and secondary endpoint than did the original Protocol for the trial. Under the Protocol the primary endpoint was progression free survival, or PFS, and the secondary endpoint was overall survival, or OS. Both of these endpoints were confounded: the PFS endpoint by pseudo-progression, and the OS endpoint by the “crossover” provision in the trial design, which allowed all of the patients in the trial to cross over to DCVax-L treatment after tumor recurrence (while remaining blinded as to which treatment they received before tumor recurrence).  The statistical analysis plan uses external control patients rather than within-study controls. There can be no assurance that regulatory authorities will allow a product approval to be based upon this approach.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164976734